Menu
In a major stride towards advancing healthcare diagnostics, Radiolife is thrilled to announce that we have been selected as a recipient of the prestigious Healthcare Solutions Grant Program, offered by the Institute for Experiential AI (IEAI). This grant program is set to empower early-stage healthcare companies, and it opens up exciting avenues for us to further our commitment to reshaping the future of healthcare.
The IEAI’s Healthcare Solutions Grant Program, made possible through funding from the Roux Institute’s Future of Healthcare Founder Residency program, is designed to provide a platform for healthcare startups like Radiolife to access cutting-edge research and expertise in the field of artificial intelligence. The Roux Institute, in partnership with Maine’s leading healthcare systems and the Maine Venture Fund, stands as a pioneer in fostering innovative solutions in the healthcare technology industry.
This grant signifies a remarkable milestone for Radiolife and our groundbreaking diagnostic technology. Radiolife developed a revolutionary medical device that can detect diseases caused by viruses, and bacteria in less than 20 seconds without the need for reagents, setting a new standard in rapid diagnostics.
Radiolife CEO, Sergio Ribeiro, expresses the significance of this achievement, stating, “The IEAI grant is a timely and significant milestone for Radiolife as we strive to revolutionize diagnostics and create a positive impact on people’s lives. This approval marks a pivotal moment in our trajectory, empowering us to harness technology and AI to reshape the future of healthcare. We are deeply grateful for this opportunity and excited to embark on this transformative journey.”
Radiolife is proud to join a select group of healthcare innovators who have been awarded this grant, demonstrating the potential of our technology and its transformative impact on the healthcare landscape. This recognition reinforces our commitment to advancing healthcare through groundbreaking AI solutions.
The IEAI’s Healthcare Solutions Grant Program reflects its dedication to merging the strengths of AI algorithms with human intelligence to address real-world problems. It also highlights the ever-growing influence of Northeastern’s global campus and the collaborative spirit between the IEAI and the Roux Institute teams.
We are excited to embark on this new chapter in our journey and are deeply thankful to the IEAI for this incredible opportunity. The future of healthcare holds immense promise, and Radiolife is committed to playing a vital role in this transformative era.
For the official release on the Healthcare Solutions Grant Program, please visit https://ai.northeastern.edu/new-grant-program-empowers-early-stage-healthcare-companies/.
Stay tuned as Radiolife continues its mission to provide rapid, cost-effective, and reagent-free diagnostics that make a difference in patients’ lives.
From left to right top (company – Name) : Jen Schlegel (119); Aarabi Balasubramanian (EmTech Care Labs); Bronwyn Bridges (PragmaClin); Kamyar Firouzi, (Althea Health); Sina Moghadam (Althea Health); Des Regan (Stratos ); Emily Sylvester (Mother of Fact); from left to right bottom: Claire Beskin (Empallo); Sergio Ribeiro (Radiolife); Ken Shapiro (Apriqot); Kevin Konty (Apriqot). Photo by Tim Greenway
We’re thrilled to announce that Radiolife has been accepted into the Future of Healthcare Program, a prestigious healthcare innovation initiative offered by The Roux Institute at Northeastern University.
The Future of Healthcare Founder Residency, a year-long program, is part of The Roux Institute’s mission to foster healthcare innovation and entrepreneurship in Maine. This innovative program is supported by leading healthcare providers, Northern Light Health and MaineHealth, along with the Maine Venture Fund. The goal is to catalyze a thriving healthtech ecosystem in Maine, benefiting patients and caregivers while offering a boost to the health tech industry.
Radiolife is one of the nine companies selected for this exclusive program. These companies, representing diverse backgrounds from three countries and five states, share a common focus on groundbreaking healthcare solutions. From artificial intelligence-powered virtual healthcare assistants to innovative medical devices, this cohort is set to make a significant impact on healthcare.
Our participation in the Future of Healthcare Founder Residency aligns perfectly with our mission to revolutionize diagnostics in healthcare.
As part of this program, each company receives a $50,000 investment, providing the necessary resources to accelerate innovation. But it’s not just about funding. The real value lies in intensive workshops, expert mentorship, and deep institutional support. The Roux Institute is fully integrated with the startups, offering more than a traditional business curriculum. Instead, the focus is on real-world experience and access to a vast network of healthcare experts, regulatory advisors, successful founders, and legal support.
Furthermore, the co-located workspace on the Portland campus fosters a collaborative atmosphere. This collaborative environment enables our startups to work closely with healthcare partners, receive feedback, and even launch potential pilot projects, thus speeding up innovation.
We’re excited to contribute to this innovative healthcare community and are proud to be part of The Roux Institute’s vision to transform the healthcare landscape. This program is a win-win-win for The Roux Institute, healthcare partners, and the startups involved. It’s also an exciting opportunity for students to gain valuable experience by working alongside healthtech innovators.
Radiolife is eager to leverage this opportunity to bring our groundbreaking diagnostic solutions to the forefront of the healthcare industry. We believe our work can significantly improve patient care, reduce healthcare costs, and drive innovation in healthcare.
The Future of Healthcare Founder Residency represents the commitment of Maine Venture Fund to fund 30 healthcare companies over three years. We’re thrilled to be a part of this initiative and its potential to elevate the healthcare system in Maine and stimulate the broader Maine economy.
The residency program has the potential to become a model for other states looking to invest and innovate in the healthcare sector. The Roux Institute’s unique role as a convenor for key healthcare players in Maine offers valuable lessons for other regions.
Radiolife and our fellow startups in the Future of Healthcare Founder Residency are ready to tackle the most pressing healthcare challenges and pioneer innovations that will shape the future of healthcare in Maine and beyond.
Meet the Companies:
– Althea (San Jose, California): Developing an artificial intelligence virtual healthcare assistant to ease staffing and burnout for healthcare providers.
– Apriqot (Scarborough, Maine): Creating a community magnifying glass that produces dynamic population health estimates to address health outcome inequities.
– Empallo (Boston): Focusing on personalized treatment plans for patients with cardiovascular diseases using machine learning models.
– EmTech Care Labs (Portland, Maine): Developing a digital platform, Care-Wallet, to assist families in managing home-based long-term care.
– Mother of Fact (Langdon, New Hampshire): Providing a digital health platform to women’s health clinics, connecting patients with registered dieticians.
– PragmaClin (St. John’s, Newfoundland and Labrador, Canada): Offering a cloud-based patient monitoring and assessment tool for neurologists to assess the progression of Parkinson’s Disease.
– Stratos Medical (Galway, Ireland): Working on its first product, TrackSmart, to make vascular access easier and less damaging during hemodialysis sessions.
– 119 (Ohio): Developing a communication tool to guide bystanders through appropriate responses in emergency situations.
Radiolife is honored to be a part of this remarkable journey, and we look forward to the innovative collaborations and groundbreaking solutions that will emerge from the Future of Healthcare Founder Residency. Together, we’ll revolutionize healthcare, improve patient outcomes, and make a meaningful difference in people’s lives.
Stay tuned for more updates and innovations from Radiolife as we embark on this exciting journey!
https://news.northeastern.edu/2023/04/27/maine-residency-program-healthtech/
We are thrilled to announce that Radiolife, a groundbreaking healthcare technology company, clinched the first-place victory at the prestigious BioTech Unicorn Battle held on February 2, 2023. This win marks a significant milestone in our journey to revolutionize diagnostics on a global scale. The event, hosted by Unicorn Events, showcased innovation and excellence in the biotechnology industry, and we are honored to have emerged as the champions.
A Victory that Ignites Our Vision
The BioTech Unicorn Battle is not just a competition; it’s a stage where game-changing ideas and innovations are put to the test. Radiolife’s victory underscores our unwavering commitment to redefining how diagnostics are conducted. Our innovative approach, which combines radiofrequency signatures and AI modeling, has the potential to transform patient care and the broader healthcare sector significantly.
Championing the Future
While our victory is a moment of celebration, it also propels us into the future, where new challenges and exciting opportunities await. Our immediate focus lies on securing the FDA Breakthrough Designation, a pivotal milestone on our path to providing groundbreaking diagnostic solutions. This designation will accelerate our journey to clinical trials, validating the effectiveness and accuracy of our technology.
Clinical Trials and Beyond
The road ahead is marked by clinical trials and the delivery of evidence that our technology is not just innovative but highly effective. We are committed to conducting rigorous clinical studies, ensuring that our diagnostic solutions meet the highest standards of accuracy and reliability. These trials are essential to achieve regulatory approvals and to prepare for scaling our impact.
Scaling the Diagnostic Revolution
Radiolife envisions a future where diagnostics are seamless, efficient, and accessible. Our technology offers results in mere seconds, eliminating the need for reagents and complex operations. The potential impact of Radiolife’s diagnostic solutions is colossal, with a serviceable obtainable market for E. coli treatments projected to reach a remarkable $3 billion by 2030. Our victory at the BioTech Unicorn Battle is a testament to the demand for innovative diagnostics, and we are poised to meet this need.
Joining the Radiolife Journey
Our victory at the BioTech Unicorn Battle is not just an accolade; it’s a call to action. We invite investors, partners, and stakeholders to join us on this transformative journey.
As we bask in the glory of our BioTech Unicorn Battle win, we look to the future with immense enthusiasm. The diagnostic revolution is underway, and Radiolife is at the forefront, driving change that will improve patient care, enhance healthcare provider capabilities, and shape the future of diagnostics.
Introduction:
In the ever-evolving landscape of healthcare, the quest for innovation knows no bounds. It is the relentless pursuit of knowledge and discovery that fuels groundbreaking advancements, and Radiolife’s patent represents the future of diagnostics positioning itself at the forefront of this movement. Today, we delve into the heart of our innovation journey, celebrating a significant milestone that not only marks our progress but also the promise of a brighter, healthier future.
Radiolife’s Patent – Future of Diagnostics:
At Radiolife, our mission is to reshape the future of diagnostics, and innovation is the compass guiding our path. We are driven by a relentless commitment to improve patient outcomes, enhance accessibility, and revolutionize the field of diagnostics. In June of 2022, our dedication bore fruit as we proudly received a Patent Grant that recognizes the transformative potential of our technology.
Unlocking the Secrets of Diagnostics:
Our innovation is based on the fusion of cutting-edge science and technology. It revolves around the ingenious concept of radio frequency signatures, combined with AI modeling. These elements work in unison to decode the intricate language of pathogens, unveiling their hidden presence in biological samples. By harnessing the power of RF signatures, we’ve unlocked a realm of possibilities previously unexplored in diagnostics.
A Beacon of Progress:
The Patent Grant bestowed upon Radiolife signifies more than legal recognition; it is a testament to the groundbreaking nature of our work. It signifies that our unique approach to diagnostics has the potential to disrupt and redefine the industry. It’s a validation of the countless hours of research, development, and dedication poured into Radiolife’s vision.
Fueling Progress Through Collaboration:
We extend our heartfelt appreciation to the brilliant minds at Stanton IP Law Firm, P.A., who have been instrumental in securing our patent. Their expertise and commitment to our cause have been invaluable in this journey of innovation.
A Glimpse into the Future:
With our patent as a cornerstone, Radiolife is poised for an exciting future. We envision a world where diagnostics are not just accurate but also rapid, accessible, and cost-effective. Our technology holds the potential to rewrite the diagnostic narrative, reducing the burden of diseases, and enhancing healthcare outcomes.
Join Us on the Journey:
The Patent Grant is not an endpoint but a stepping stone towards a brighter tomorrow. Radiolife’s Patent is the Future of Diagnostics and we invite you to join us on this extraordinary journey of innovation, collaboration, and impact. As we celebrate this achievement, we also look forward to the countless possibilities that lie ahead.
Conclusion:
In the quest to Promote the Progress of Science and Useful Arts, Radiolife stands as a beacon of progress, driven by innovation and a relentless commitment to improving healthcare. Our Patent Grant signifies the dawn of a new era in diagnostics, and we are excited to share this journey with you.
Stay tuned as we continue to push the boundaries of what’s possible in diagnostics, reshaping the future one breakthrough at a time.
A Radiolife assinou na última sexta-feira (29/01), termo de parceria com a Secretaria Estadual de Saúde do Espírito Santo (Sesa), por meio do Instituto Capixaba de Ensino, Pesquisa e Inovação (ICEPi).
De acordo com o compromisso, o objetivo é a realização de testes de calibragem final do Cube Scan, equipamento em desenvolvimento na empresa para diagnóstico do novo Coronavírus (Sars-Cov-2).
A solenidade de assinatura do documento ocorreu na sede da Sesa, em Vitória. Da Radiolife, estiveram presentes o engenheiro eletricista e co-fundador Willians Dias e o representante legal Jean Magno. A Sesa foi representada pelo secretário estadual de Saúde, Nésio Fernandes, pelo diretor-geral do ICEPi, Daniel Henrique Rezende e pelo diretor do Lacen, Rodrigo Rodrigues. A partir desse compromisso, a RadioLife disponibilizará o equipamento e pessoal para operá-lo no âmbito da Sesa. O objetivo é finalizar os testes clínicos com amostras do vírus causador da covid-19.
O período de testes engloba os próximos 30 dias e pode ser prorrogado por igual período. “Essa parceria é fundamental para a acreditação final do Cube Scan. Ele já foi testado e calibrado em outras oportunidades, apresentando ótimas taxas de sucesso”, destacam os proprietários da Radiolife.
Baseada em tecnologia de radiofrequência, a solução para diagnóstico da covid-19 apresenta resultado em 10 segundos e não exige o uso de reagentes. A ideia surgiu a partir da observação das dificuldades relacionadas aos exames rápidos e ortomoleculares, como preço, capacidade de processamento e data de coleta.
O equipamento já foi testado com sucesso em laboratórios nacionais. Agora, começa a fase final de testes na Sesa. Paralelamente, a empresa busca autorizações junto à Agência Nacional de Vigilância Sanitária (Anvisa) para comercialização do aparelho. Saiba mais sobre o Cube Scan aqui.
A Radiolife é uma empresa de tecnologia e inovação na área de tratamento e diagnóstico. A Radiolife é uma startup incorporada em Delaware, com presença também no Vale do Silício, onde realiza atividades de pesquisa e desenvolvimento. Anteriormente à pandemia de Covid-19, já tinha soluções patenteadas para a área de saúde. Entre elas, uma tecnologia para diagnóstico e tratamento de câncer. Essa patente e o Cube Scan são baseados em tecnologia de radiofrequência.
Após os primeiros resultados alcançados, a Radiolife e sua tecnologia vem ganhando destaque na mídia.
Desde março de 2020, a Radiolife vem investindo em sua tecnologia para diagnóstico do Covid-19. Para atingir melhores resultados e confiabilidade, a startup vem firmando parcerias com laboratórios nacionais para validação de sua tecnologia.
No dia 30 de dezembro, o jornal Tribuna On Line trouxe reportagem sobre o Cube Scan. O equipamento em desenvolvimento na Radiolife detecta o novo coronavírus de maneira rápida e eficiente.
Dentre outros pontos, a matéria enfatizou aspectos importantes sobre a tecnologia, como por exemplo:
A reportagem destaca também que a startup está buscando o registro do equipamento perante as autoridades competentes. “Estamos em fase de desenvolvimento e em conversa com órgãos públicos para obtenção das autorizações necessárias. Assim que obtivermos essas autorizações, iremos disponibilizar no mercado brasileiro”, informou um dos fundadores da Radiolife, Sérgio Schirmer.
Veja aqui a matéria do jornal Tribuna On Line na íntegra.
Veja também outras matérias que saíram sobre a tecnologia da Radiolife: Radiolife saiu na Mídia
English 
Portuguese